JNBA Financial Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

JNBA Financial Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.21K	Hold	4	–	–	﹤0.01%	763
2026 Q1	$1.32K	Hold	4	–	–	﹤0.01%	770
2025 Q4	$1.59K	Buy	+4	New	+$1.77K	﹤0.01%	693
2025 Q1	–	Sell	-4	Closed	-$942	–	651
2024 Q4	$942	Hold	4	–	–	﹤0.01%	622
2024 Q3	$1.1K	Hold	4	–	–	﹤0.01%	625
2024 Q2	$972	Hold	4	–	–	﹤0.01%	607
2024 Q1	$598	Hold	4	–	–	﹤0.01%	650
2023 Q4	$766	Hold	4	–	–	﹤0.01%	662
2023 Q3	$709	Buy	+4	New	+$763	﹤0.01%	693

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JNBA Financial Advisors's ALNY Position: Q2 2026 in Review

JNBA Financial Advisors held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 4 shares worth $1.21K. The position accounts for ﹤0.01% of the portfolio, ranked #763.

JNBA Financial Advisors first reported a position in ALNY in Q3 2023 and has held it in 9 quarters since. The position peaked at $1.59K in Q4 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

JNBA Financial Advisors held 4 shares of Alnylam Pharmaceuticals worth $1.21K as of Q2 2026.
JNBA Financial Advisors left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
Alnylam Pharmaceuticals made up ﹤0.01% of JNBA Financial Advisors's portfolio in Q2 2026, its #763 holding.
JNBA Financial Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2023 and has held it in 9 quarters since.
JNBA Financial Advisors's Alnylam Pharmaceuticals position peaked at $1.59K in Q4 2025.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on JNBA Financial Advisors's 13F filing for Q2 2026, filed 23 Jul 2026.